Wednesday, Jan 08, 2014
TOKYO – Japan’s health ministry plans to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug.Novartis Pharma KK has been under fire since a university said the data in clinical studies might have been skewed to promote Valsartan.
A ministry panel of experts concluded in September that Novartis Pharma KK should be held responsible for studies at various universities that used manipulated data on the drug.
The firm used data from the studies to market its drug, playing up its supposed additional benefits.
Tokyo’s Jikei University School of Medicine has retracted research that appeared in respected medical journal The Lancet six years ago due to data fabrication.
Kyoto Prefectural University of Medicine also concluded that its studies on the drug used incomplete clinical data.
Chiba University said in December it could not find intentional data fabrication but researchers failed to disclose 91 million yen ($880,000) in scholarship donations from the pharmaceutical company in the three years from 2007 to 2009.